Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas

NCT00647764 is registered in ClinicalTrials.gov with Esanex Inc. as lead sponsor.

NCT NCT00647764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00647764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
Lead sponsor
Esanex Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2008
Completion date
September 30, 2010
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoid malignancy (lymphoma and cll), lymphoma, solid tumor malignancy